Background
==========

Blockade of the sphenopalatine ganglion with OnabotulinumtoxinA injections (SphenoBlock) represents a novel approach for treating intractable chronic cluster headache (iCCH).

Aim
===

The aim of this pilot study was to explore the safety aspects and therapeutic potential of SphenoBlock.

Method
======

After signing written confirmed consent ten patients with iCCH were injected with 25 U (n=5) or 50 U (n=5) onabotulinumtoxinA towards the sphenopalatine ganglion in an observational study, approved by the Institutional Review Board, with 6 months follow-up. The procedure was performed with a novel image-guided technique. The primary endpoint was to evaluate safety of the procedure, but change in attack frequency from baseline to week 4, 12 and 24 was also registered.

Results
=======

Data for the first 5 patients are presented. One patient experienced intermittent ipsilateral visual deficits lasting 4 weeks. Patient number 5 was a failed injection. Four patients were defined as frequency responders (\>50% reduction from baseline) in week 4, 3 patients responded in week 12, and 2 patients in week 24 (Figure [1](#F1){ref-type="fig"}). Complete study data will be presented at the meeting.
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Conclusion
==========

SphenoBlock in iCCH shows promising preliminary results and give reasons for cautious optimism for further studies on this low-cost alternative treatment of iCCH.
